RNA News and Research

RSS

Ribonucleic acid (RNA) is a biologically important type of molecule that consists of a long chain of nucleotide units. Each nucleotide consists of a nitrogenous base, a ribose sugar, and a phosphate.

Researchers find how olfactory receptor variation impacts human odor perception

According to Gertrude Stein, "A rose is a rose is a rose," but new research indicates that might not be the case when it comes to the rose's scent. Researchers from the Monell Center and collaborating institutions have found that as much as 30 percent of the large array of human olfactory receptor differs between any two individuals. This substantial variation is in turn reflected by variability in how each person perceives odors.

9 Dec 2013

Johns Hopkins researchers discover some cases of scleroderma likely to be initiated by cancer

The Scleroderma Research Foundation today reported that researchers at The Johns Hopkins University have discovered that some cases of scleroderma are likely to have been initiated by cancer.

6 Dec 2013

Scientists receive $4M grant to identify biomarker for secondary injuries associated with brain

In an effort to lower medical costs, identify patients at risk for injury, and speed patient recovery, scientists will attempt to identify a molecular signal that indicates severity of brain-injury during a $4 million, five-year federal grant to Barrow Neurological Institute at St. Joseph's Hospital and Medical Center, Phoenix Children's Hospital and the Translational Genomics Research Institute (TGen).

5 Dec 2013

Senesco completes cohort 3 of SNS01-T Phase 1b/2a trial for multiple myeloma and lymphoma treatment

Senesco Technologies, Inc. reported today the completion of cohort 3 of its Phase 1b/2a clinical trial for its drug, SNS01-T, for the treatment of multiple myeloma and lymphoma. The Company has also received approval from its Data Review Committee to proceed to cohort 4, which is expected to require six evaluable patients.

5 Dec 2013

Enrollment opens for IMO-8400 Phase 1/2 trial in patients with Waldenström's macroglobulinemia

Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that enrollment is open for a Phase 1/2 clinical trial of IMO-8400 in patients with Waldenström's macroglobulinemia, following acceptance of its Investigational New Drug application by the U.S. Food and Drug Administration.

5 Dec 2013

MassBiologics gets FDA orphan drug designation for MBL-HCV1 antibody

MassBiologics of the University of Massachusetts Medical School has received an orphan drug designation from the U.S. Food and Drug Administration for MBL-HCV1, a monoclonal antibody developed to prevent hepatitis C virus recurrence in patients receiving a liver transplant.

5 Dec 2013

Finding identifies new mechanism that could contribute to the pathology of ALS

RNA molecules, used by cells to make proteins, are generally thought to be "silent" when stowed in cytoplasmic granules. But a protein mutated in some ALS patients forms granules that permit translation of stored RNAs, according to a study in The Journal of Cell Biology. The finding identifies a new mechanism that could contribute to the pathology of the disease.

4 Dec 2013

New biomarkers to improve diagnostics of prostate cancer

New biomarkers will improve diagnostics of endemic diseases in future, such as prostate cancer. Their mission: to recognize the tumor earlier and classify it more precisely - thereby helping avoid unnecessary operations.

2 Dec 2013

Cyclin D1 protein controls cell cycle progression, microRNA biogenesis in breast cancer

Cyclin D1, a protein that helps push a replicating cell through the cell cycle also mediates the processing and generation of mature microRNA, according to new research publishing November 29 in Nature Communications. The research suggests that a protein strongly implicated in human cancer also governs the non-protein-coding genome. The non-coding genome, previously referred to as junk DNA, makes up most of the human genome, and unlike the coding genome, varies greatly between species.

29 Nov 2013

Scientists design small synthetic molecules capable of blocking AIDS virus replication

A multidisciplinary team of scientists from Spanish universities and research centres, among which is the University of Valencia, has managed to design small synthetic molecules capable of joining to the genetic material of the AIDS virus and blocking its replication.

28 Nov 2013

Drugs delivered by nanoparticles hold promise for targeted treatment of many diseases, including cancer

Drugs delivered by nanoparticles hold promise for targeted treatment of many diseases, including cancer. However, the particles have to be injected into patients, which has limited their usefulness so far.

27 Nov 2013

CRI researcher receives grant from DIPG to research on pediatric brain tumors

Javad Nazarian, PhD, a researcher with Children's Research Institute (CRI) at Children's National, is the recipient of a $99,979 grant from the DIPG Collaborative for his proposal entitled, "Comparative Proteomic and RNA Sequencing of DIPGs."

27 Nov 2013

Research: Motor proteins transport mRNA to get where it is needed, prevent diseases

Scientists have found that mRNA may travel one way down a cell, then board another, aptly named motor protein, and head in the opposite direction to get where it ultimately needs to be.

27 Nov 2013

UMass Medical School licenses "anti-gal" technology to Agalimmune

The University of Massachusetts Medical School has licensed "anti-gal" technology developed by Professor of Surgery and Medicine Uri Galili, PhD, to newly formed biopharmaceutical company Agalimmune Ltd. for the purpose of developing innovative immunotherapies for the treatment of solid tumor cancers. Agalimmune is supported by an investment group comprising Loxbridge Research LLP and Animatrix Capital LLP and is based in London and California.

27 Nov 2013

Bruker receives FDA clearance to market MALDI Biotyper CA System in the U.S.

Bruker Corporation today announced that it has been granted U.S. FDA clearance under Section 510(k) to market its MALDI Biotyper CA System in the United States for the identification of Gram negative bacterial colonies cultured from human specimens.

26 Nov 2013

HIV patients face higher risk of virologic failure than previously thought

People with human immunodeficiency virus (HIV) run a higher risk of virologic failure than previously thought, even when their number of RNA copies of the retrovirus per millilitre of blood is slightly above the detection threshold, according to a study by Claudie Laprise at the University of Montreal's Department of Social and Preventative Medicine.

26 Nov 2013

Researchers successfully target T lymphocytes which play key role in body's immune response

Researchers at the University of California, San Diego School of Medicine have successfully targeted T lymphocytes - which play a central role in the body's immune response - with another type of white blood cell engineered to synthesize and deliver bits of non-coding RNA or microRNA (miRNA).

26 Nov 2013

Researchers reveal why some breast cancer cells are resistant to chemotherapy

Researchers at the UNC School of Medicine, working with cell lines in a lab, have discovered why some of the most aggressive and fatal breast cancer cells are resistant to chemotherapy, and UNC scientists are developing ways to overcome such resistance.

26 Nov 2013

Seed grants support cancer diagnosis and treatment, vascular health research

Five teams of scientists earned research seed grants awarded this year by the John S. Dunn Foundation. The awards support new collaborations by researchers at Rice University's BioScience Research Collaborative (BRC) and their partners at other institutional members of the Gulf Coast Consortia (GCC).

26 Nov 2013

Cleveland Clinic researchers elected as AAAS Fellows for excellent contributions to science

Cleveland Clinic researchers Richard A. Padgett, Ph.D., and Edward F. Plow, Ph.D., have been named Fellows of the American Association for the Advancement of Science (AAAS). This year's AAAS Fellows will be formally announced in the AAAS News & Notes section of the journal Science on Nov. 29, 2013.

26 Nov 2013

RNA News and Research

Further Reading

Researchers find how olfactory receptor variation impacts human odor perception

Johns Hopkins researchers discover some cases of scleroderma likely to be initiated by cancer

Scientists receive $4M grant to identify biomarker for secondary injuries associated with brain

Senesco completes cohort 3 of SNS01-T Phase 1b/2a trial for multiple myeloma and lymphoma treatment

Enrollment opens for IMO-8400 Phase 1/2 trial in patients with Waldenström's macroglobulinemia

MassBiologics gets FDA orphan drug designation for MBL-HCV1 antibody

Finding identifies new mechanism that could contribute to the pathology of ALS

New biomarkers to improve diagnostics of prostate cancer

Cyclin D1 protein controls cell cycle progression, microRNA biogenesis in breast cancer

Scientists design small synthetic molecules capable of blocking AIDS virus replication

Drugs delivered by nanoparticles hold promise for targeted treatment of many diseases, including cancer

CRI researcher receives grant from DIPG to research on pediatric brain tumors

Research: Motor proteins transport mRNA to get where it is needed, prevent diseases

UMass Medical School licenses "anti-gal" technology to Agalimmune

Bruker receives FDA clearance to market MALDI Biotyper CA System in the U.S.

HIV patients face higher risk of virologic failure than previously thought

Researchers successfully target T lymphocytes which play key role in body's immune response

Researchers reveal why some breast cancer cells are resistant to chemotherapy

Seed grants support cancer diagnosis and treatment, vascular health research

Cleveland Clinic researchers elected as AAAS Fellows for excellent contributions to science

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News